2,264 press releases in English indexed under biotech & pharma.
Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions
Press release – No. 20 / 2026
Key Takeaways Clinical trials require guard railed AI that's purpose built for the regulated industry that has high human stakes and required audit trails. Sofia helps make complex, fast-moving trial data more accessible to study teams who manage large volumes of time-sensitive work. Study teams can get faster answers and take confident action. Sofia goes beyond information retrieval and can execute authorized system
Target North America and invest in targeted delivery and programmable cell-engineering to unlock new revenue streams in precision medicine. Target North America and invest in targeted delivery and programmable cell-engineering to unlock new revenue streams in precision medicine.
Collaboration Targets Government and Institutional Procurement with Six-Month Exclusivity Collaboration Targets Government and Institutional Procurement with Six-Month Exclusivity
Acquisition of Velaris and concurrent oversubscribed $350 million private placement positions the Company to deliver multiple proof-of-concept datasets in pulmonary arterial hypertension
Randomized, placebo-controlled study in 16 cognitively unimpaired participants met safety and immunogenicity objectives; all 12 vaccine recipients developed anti-Aβ antibodies after two priming doses Randomized, double-blind, placebo-controlled Phase 1 trial enrolled 16 cognitively...
CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor conferences:
EMERYVILLE, Calif., Oct. 13, 2026 -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a panel discussion titled “Genome Editing: Next-Wave Platforms Beyond CRISPR 1.0” at the Chardan 10th Annual Healthcare Conference on Tuesday, October 20, 2026, at 10:30 a.m. ET, being held in New York, NY.
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
Funding will advance translational readiness across Envisagenics’ cancer-specific programs for internal development and strategic partnering
Company will present on a single-dose escalation study of TMB-365 and on resistance in the context of the long-acting TMB-365 and TMB-380 maintenance regimen in people living with HIV Company will present on a single-dose escalation study of TMB-365 and on resistance in the context of the long-acting TMB-365 and TMB-380 maintenance regimen in people living with HIV